IL-10 and integrin signaling pathways are associated with head and neck cancer progression

BMC Genomics

Volumn 17, Issue 1, 2016, Pages

  Bornstein, Sophia ^a   Schmidt, Mark ^a   Choonoo, Gabrielle ^a   Levin, Trevor ^b   Gray, Joe ^a,b   Thomas, Charles R ^a   Wong, Melissa ^a   McWeeney, Shannon ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Oregon Health and Science University Department of Biomedical Engineering   (United States)

Author keywords

CTCF; Head and neck cancer; HNSCC; IL 10; Integrin; Mutation; RNA seq; Signature; TCGA

Indexed keywords

ANTINEOPLASTIC AGENT; INTEGRIN; INTERLEUKIN 10; INTERLEUKIN 6; STAT5A PROTEIN; TRANSCRIPTION FACTOR CTCF; CCCTC-BINDING FACTOR; IL10 PROTEIN, HUMAN; REPRESSOR PROTEIN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BLVRB GENE; C1ORF43 GENE; CA5A GENE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CREB3 GENE; CTCF GENE; FEMALE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HEAD AND NECK CANCER; HRH4 GENE; HUMAN; IL 6 GENE; INTRACELLULAR SIGNALING; KRTAP19 1 GENE; LEP GENE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PAGE4 GENE; PAGE5 GENE; SEZ6L GENE; SMTNL1 GENE; SOMATIC MUTATION; STAT5A GENE; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; VTN GENE; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HEAD AND NECK NEOPLASMS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INTEGRINS; INTERLEUKIN-10; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PROGNOSIS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION;

EID: 84953408743     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-015-2359-6     Document Type: Article

References (20)

1. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11(1):21-28.
2. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359(11):1116-1127.
3. Cancer Genome Atlas N: Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015, 517(7536):576-582.
4. Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. Interactions between coagulation and complement--their role in inflammation. Seminars in immunopathology 2012, 34(1):151-165.
5. Mroz EA, Tward AM, Hammon RJ, Ren Y, Rocco JW. Intra-tumor Genetic Heterogeneity and Mortality in Head and Neck Cancer: Analysis of Data from The Cancer Genome Atlas. PLoS medicine 2015, 12(2):e1001786.
6. Wang W, Lim WK, Leong HS, Chong FT, Lim TK, Tan DS, et al. An eleven gene molecular signature for extra-capsular spread in oral squamous cell carcinoma serves as a prognosticator of outcome in patients without nodal metastases. Oral Oncol 2015.
7. Libby RT, Hagerman KA, Pineda VV, Lau R, Cho DH, Baccam SL, et al. CTCF cis-regulates trinucleotide repeat instability in an epigenetic manner: a novel basis for mutational hot spot determination. PLoS genetics 2008, 4(11):e1000257.
8. Marshall AD, Bailey CG, Rasko JE. CTCF and BORIS in genome regulation and cancer. Current opinion in genetics & development 2014, 24:8-15.
9. Eke I, Zscheppang K, Dickreuter E, Hickmann L, Mazzeo E, Unger K, et al. Simultaneous beta1 integrin-EGFR Targeting and Radiosensitization of Human Head and Neck Cancer. J Natl Cancer Inst 2015, 107(2).
10. Vermorken JB, Peyrade F, Krauss J, Mesia R, Remenar E, Gauler TC, et al. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). Ann Oncol 2014, 25(3):682-688.
11. Bonomi M, Patsias A, Posner M, Sikora A. The role of inflammation in head and neck cancer. Adv Exp Med Biol 2014, 816:107-127.
12. Bornstein S, White R, Malkoski S, Oka M, Han G, Cleaver T, et al. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. The Journal of clinical investigation 2009, 119(11):3408-3419.
13. Oft M: IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer immunology research 2014, 2(3):194-199.
14. Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 2014, 50(7):627-632.
15. R Core Team (2014). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.
16. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139-40.
17. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research 2003, 13(11):2498-2504.
18. Wu G, Feng X, Stein L. A human functional protein interaction network and its application to cancer data analysis. Genome Biol. 2010;11(5):R53.
19. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214-8.
20. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-50.